Polyphron
Polyphron makes lab-grown and simulated human micro-tissues to test drug ideas.
01What it doesPolyphron makes lab-grown and simulated human micro-tissues to test drug ideas.Source-grounded · automated review · Explore ↗
Checked 2026-09-19 · Review due 2026-09-26
Read supporting source ↗Their platform combines the Tissue…
02Who is involvedEvidence still neededOpen review status ↗
The investor names and roles are supported for the Seed financing: Quiet Capital led; Gradient, Haystack, and Compound participated. However, the target round is Pre-Seed while the documented and drafted event is Seed, so this field does not match the target financing event.
03What happenedEvidence still neededOpen review status ↗
Document 0 supports that Polyphron raised $20M in Seed financing and that FinSMEs dated the item 17/09/2026. The amount is financing, not valuation. However, the target specifies Pre-Seed, not Seed, so the transaction does not match the target event.
04Why it mattersIts tissue system may help drug developers test ideas against human-like biology earlier.Interpretation · Explore ↗
Polyphron · Financing Record
Explore source-linked visual explanations for Polyphron. Unsupported claims are withheld while source review continues.
Record 12637 · Recorded date: Needs review
Explore company records →